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Abstract
Objective: We tested the hypothesis that patients with difficult asthma have an increased frequency of certain genotypes
that predispose them to asthma exacerbations and poor asthma control.
Methods: A total of 180 Caucasian children with confirmed asthma diagnosis were selected from two phenotypic groups;
difficult (n = 112) versus mild/moderate asthma (n = 68) groups. All patients were screened for 19 polymorphisms in 9
candidate genes to evaluate their association with difficult asthma.
Key Results: The results indicated that LTA4H A-9188.G, TNFa G-308.A and IL-4Ra A1727.G polymorphisms were
significantly associated with the development of difficult asthma in paediatric patients (p,0.001, p = 0.019 and p= 0.037,
respectively). Haplotype analysis also revealed two haplotypes (ATA haplotype of IL-4Ra A1199.C, IL-4Ra T1570.C and IL-
4Ra A1727.G and CA haplotype of TNFa C-863.A and TNFa G-308.A polymorphisms) which were significantly associated
with difficult asthma in children (p = 0.04 and p= 0.018, respectively).
Conclusions and Clinical Relevance: The study revealed multiple SNPs and haplotypes in LTA4H, TNFa and IL4-Ra genes
which constitute risk factors for the development of difficult asthma in children. Of particular interest is the LTA4H A-
9188.G polymorphism which has been reported, for the first time, to have strong association with severe asthma in
children. Our results suggest that screening for patients with this genetic marker could help characterise the heterogeneity
of responses to leukotriene-modifying medications and, hence, facilitate targeting these therapies to the subset of patients
who are most likely to gain benefit.
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Introduction
Asthma is one of the most common diseases worldwide [1]. It
affects an estimated 300 million individuals, resulting in substantial
morbidity, mortality, and health care utilisation. It has been
estimated that about 4% of the British and North American
population have asthma. Mortality from asthma occurs in
approximately 0.4 per 100,000 and is currently estimated at
about 1,500 per annum in the UK [2]. Asthma is not a curable
disease, therefore, the goal of treatment is to control asthma
symptoms and obtain a better quality of life for patients through
maintaining normal or near normal lung function and preventing
pulmonary exacerbations [3].
National and international treatment guidelines such as the
British Thoracic Society and the Scottish Intercollegiate Guide-
lines Network [3], advocate the importance of anti-inflammatory
agents in the management of chronic asthma symptoms. However,
there is a subgroup of patients who are still insufficiently controlled
on the maximal dose of asthma therapy, particularly in relation to
inhaled corticosteroid (ICS) [4]. This subgroup of patients is
known as difficult-to-treat asthma patients or in short patients with
‘difficult asthma’. There is no universally agreed definition for
difficult asthma, although the term has been adopted by the
European Respiratory Society (ERS) in 1999 [5]. According to the
ERS, difficult-to-treat asthma includes ‘‘patients on high doses of
control medication who either have or have not achieved control
at this level of treatment’’ [6]. These patients are considered a
source of significant concern as they suffer from continued
impaired lung function and frequent exacerbations which predis-
pose them to life threatening attacks and asthma-related death. In
addition, they are at a higher risk of developing adverse drug
effects, in particular due to high doses of steroid therapy (both
inhaled and oral) [7].
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Only one half of children referred to secondary or tertiary care
clinics with apparent difficult asthma have true severe therapy
resistant asthma (STRA). The remainder have difficult to treat
asthma (DTA) but have not been instituted correct basic asthma
management. This includes poor inhaler technique, inadequate
medication adherence and exposure to on-going triggers of
airways inflammation [4]. In addition to the multiple and complex
factors that may contribute to uncontrolled symptoms, genetic
predisposition is considered an important factor [8]. For example,
available data from previous pharmacogenetic studies, suggests
that as much as 70% of the variability in therapeutic responses to
pharmacotherapy is genetically determined [9–11].
A number of polymorphisms in genes encoding for different
enzymes, receptors and cytokines that are involved in asthma drug
therapy and inflammation pathways, have been associated with
asthma and/or asthma-related phenotypes in various studies [12–
19]. These include genes encoding the b2-adrenergic receptor
(ADRb2), corticotrophin releasing hormone receptor 1 (CRHR1),
leukotriene C4 synthase (LTC4S), leukotriene A4 hydrolase
(LTA4H), interleukin-4 (IL-4), interleukin-13 (IL-13), interleukin-
4 receptor a (IL-4Ra), tumour necrosis factor a (TNFa) and
lymphotoxin a (LTA, alternative name: TNFb). A key question,
therefore, is whether subjects with certain genotypes fail to achieve
asthma control and hence become classified as having difficult
asthma.
The aim of the present study was to investigate whether patients
with difficult asthma have an increased frequency of certain
genotypes that predispose them to asthma exacerbations and poor
asthma control. The presence of such an association will support
the hypothesis that inappropriate treatment regimens, can lead to
the development of a complex group of difficult asthmatics. As it is
unlikely that only one genetic marker could significantly predict
disease pathogenesis or drug response, 19 representative SNPs of
relevant polymorphisms in nine candidate genes (ADRb2,
CRHR1, LTC4S, LTA4H, IL-4, IL-13, IL-4Ra, TNFa and
LTA) and their common haplotypes were investigated in the
present study in one ethnic group, a Caucasian population. This is
the first study to examine the relationship between difficult asthma
and these polymorphisms of interest in children.
Methods
Ethics statement
The study was approved by the Office for Research Ethics
Committees in Northern Ireland (Ref no. 08/NIR02/18). Patients
were included in the study only after their parents or legal
guardians had been fully informed and had signed the study
consent form. In addition, verbal assent was obtained from older
children ($6 years) before enrolment into the study.
Study subjects
A total of 180 Caucasian children with confirmed asthma
diagnosis were recruited into the study from 5 paediatric
outpatient clinics in four different centres in Northern Ireland
(the Royal Belfast Hospital for Sick Children, Cupar Street
Asthma Clinic N&W Belfast, Craigavon Area Hospital and Ulster
Hospital) and 3 primary care centres. Asthmatic children (under
16 years old) attending the clinics were classified into two: 1]
Difficult to treat asthma, DTA (n = 112) and 2] mild/moderate
asthma (n = 68) groups. DTA groups were recruited mainly from
the hospital outpatient clinics while the majority of mild/moderate
(M/M) asthma patients were recruited from the participating
primary care centres. The classification of DTA was based on on-
going asthma symptoms despite treatment with at least 800
micrograms (400 micrograms for children ,5 years) of inhaled
corticosteroid, ICS. Children over 5 years of age were taking
additional long-acting beta 2 agonist while for those under 5 years
a leukotriene antagonist was added mirroring steps 4 and 5 or the
British Thoracic Society Guidelines (step 3/4 in children ,5 years
old) [3]. It is routine practice at the asthma clinics for inhaler
technique to be checked, adherence to be assessed by child/
parental questioning and for home trigger factors to be determined
and avoidance advice given, but no home visits are arranged. The
Mild/Moderate (MM) asthma classification was used for children
whose asthma was readily controlled on a smaller dose of ICS.
Study design
Buccal swabs were obtained from patients (one swab per
individual) during the clinic visit. In the present study, SK-2
Isohelix buccal swabs (Ishohelix, Cell Projects Ltd, Kent, UK)
were used for collecting cheek cells for the purpose of DNA
extraction. Participants were advised not to consume any food or
drink 30 minutes prior to sample collection. The samples were
kept at 220uC for no longer than four weeks before DNA
extraction.
Patient demographic details as well as clinical and medical
characteristics were obtained directly from patients and/or their
parents (through a structured questionnaire) and from their
medical charts. Data collected for each patient included: age,
gender, weight, age at diagnosis, prescribed medications and their
dosages, passive smoking status, personal and family history of
hay-fever and/or eczema, non-asthma related co-morbidity,
records of medication side effects experienced and records of
asthma exacerbations (defined as unscheduled clinic visits or
hospitalisations within the previous 12 months).
Genotyping the polymorphisms of interest
All patients were screened for 19 polymorphisms in nine
candidate genes (ADRb2, CRHR1, LTC4S, LTA4H, IL-4, IL-
13, IL-4Ra, TNFa and LTA) to evaluate their association with
difficult asthma. The polymorphisms selected in the present study
were either functional SNPs or SNPs which have been reported
and implicated with clinical relevance in the literature. For
instance, A46.G and C79.G polymorphisms in the gene
encoding the human b2-adrenoceptor have been shown to alter
its function in the cardiovascular and respiratory systems [12,20–
21]. LTC4S A-444.C and LTA4H A-9188.G polymorphisms
have been associated with altered response to leukotriene
antagonists [13–14]. Furthermore, G35892.T, A38952.G and
G54898.A polymorphisms in the CRHR1 gene were associated
with alterations in the therapeutic responses to inhaled corticoste-
roids in asthmatic patients [15].
Other polymorphisms in genes related to T helper cell (Th)
pathway have been associated with asthma and related phenotypes
(including TNFa T-1031.C, C-863.A and G-308.A polymor-
phisms, LTA C804.A, and C-1111.T and G431.A polymor-
phisms in IL-13 gene) [17–19,22–23]. In addition, polymor-
phisms in both IL-4 and IL4-Ra (C-590T and C-33.T in IL-4
and A223.G, A1199.C, T1570.C and A1727.G SNPs in
IL4-Ra) have been associated with severity of asthma as measured
by FEV1 and asthma exacerbations in recent studies [16–17,24].
In the present study, genomic DNA was extracted from SK-2
swabs using the QIAmpH DNA mini kit protocol for buccal swabs
(Qiagen, Hilden, Germany). The concentration of the extracted
DNA was quantified using a NanoDrop 1000H spectrophotometer
(Thermo Fisher Scientific, Delaware, USA) according to the
manufacturer’s instructions. Detection of the various SNPs of
interest was carried out using the SequenomH MassARRAY
Pharmacogenetics of Difficult Asthma in Children
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genotyping platform (iPlex assay, SequenomH, Hamburg, Ger-
many) and the validated TaqManH genotyping assays obtained
from Applied Biosystems (ABI, Foster City, USA).
The possibility of detecting the various SNPs of interest using
the iPlex systems of the SequenomH platform was assessed using
the MassARRAY Assay Design software (SequenomH, Hamburg,
Germany). The highest plex level that could be achieved, however,
was a bundle of 9 SNPs which included ADRb2 A46.G, LTC4S
A-444.C, LTA4H A-9188.G, CRHR1 A38952.G, CRHR1
G54898.A, IL-4 C-33.T, IL-4Ra T1570.C, IL-4Ra
A1727.G and IL-13 C-1111.T SNPs. Approximately 15 ng of
genomic DNA was used to genotype each sample. The DNA
samples were amplified by multiplex polymerase-chain reactions
(PCR), and the PCR products were then used for locus-specific
single-base extension reactions. The resulting products were
desalted and spotted into a 384-element SpectroCHIP array and
then subjected to the MALDI-TOF mass spectrometry. Spectro-
TYPER software was used for the identification of SNP-specific
signals and for automatic genotype calling.
The remaining 10 SNPs (ADRb2 C79.G, CRHR1
G35892.T, IL-4 C-590.T, IL-13 G431.A, IL-4Ra A223.G,
IL-4Ra A1199.C, TNFa T-1031.C, TNFa C-863.A, TNFa
G-308.A and LTA C804.A) were genotyped using TaqManH
genotyping assays. The TaqManH primer/probe set designed for
each SNP allele was included in the kits purchased from Applied
Biosystems (ABI, Foster City, USA). TaqManH PCR reactions
were performed in a 384-well format in a 5 ml reaction mixture
containing 2.5 ml TaqManH universal PCR master mix and using
an amplification protocol of 95uC for 10 min, followed by 45
cycles of 92uC for 15 sec, then 60uC for 1 min. An allelic
discrimination analysis was carried out using the ABI7900HT
sequence detection system (ABI, Foster City, USA).
All sample plates contained cases, controls, blanks and duplicate
samples. Quality control measures included independent double
genotyping and, where available, comparison of our genotypes to
those in the Hapmap database (http://www.hapmap.org/). All
genotyping analysis was performed within the Genomic Core
Facility, Queen’s University Belfast.
Statistical analysis
Statistical analysis was performed using SPSSH computer
software (version 19; SPSS Inc, Chicago, IL, USA). Results were
expressed as the mean and 95% confidence intervals or as
frequencies (in the case of allele or haplotype carriers in patient
groups). The difference in the clinical and medical characteristics
between the two asthmatic groups (difficult and M/M) was
investigated using the Chi-square (x2) test (categorical variables)
and Mann-Whitney U-test (non-parametric test for continuous
variables).
All markers were tested for deviation from the Hardy-Weinberg
Equilibrium (HWE) in both M/M and difficult asthmatic groups
using a Chi-square (x2) goodness-of-fit test, before analysis to
evaluate the accuracy of genotyping. The difference in allele
frequencies and genotype distribution of each polymorphism
between the two asthmatic groups (difficult versus M/M) were
compared using the Chi-square (x2) test or the Fisher-Exact test as
appropriate. Odds ratio (OR) were also calculated using binary
logistic regression with 95% confidence intervals (CI). We
considered two genetic models for genotype analysis: dominant
(homozygote allele 1 vs. heterozygote plus homozygote allele 2)
and recessive (homozygote allele 1 plus heterozygote vs. homozy-
gote allele 2). Statistical significance was set at a p-value ,0.05.
Power analysis calculations to estimate the number of subjects
needed to detect significant ORs assuming average allele
frequencies in the control population was carried out using the
statistical software package StatCalc (version 7.1.0.6; Epi InfoTM,
Atlanta GA, USA).
Haplotype analysis was performed using the HaploviewH
programme (version 4.2) and blocks were identified using the
confidence intervals method by Gabriel et al. [25]. Correction for
multiple testing was performed using permutation correction
(n = 100,000) by the Haploview program [26]. This approach
corrects for multiple testing but takes into account the correlation
between markers [26]. Finally, the presence of gene-gene
interactions was determined using the likelihood algorithms
implemented in the program UNPHASED [27]. Specifically,
individual SNPs that were significantly associated with asthma
severity after correction for multiple testing were chosen for
further analysis of gene-gene interactions.
Results
Subject characteristics
A total of 180 children with asthma were enrolled in this study.
These included 112 with difficult asthma and 68 with M/M
asthma. More than half of the participants were male (64.4%) and
the mean age was 9.1 years old. The majority of children with
difficult asthma (90.2%) had at least one indicator of asthma
exacerbation in the preceding 12 months; 76% had unscheduled
GP or hospital visits, 34% had A&E attendances, 25% had
hospital admissions and 76% had a rescue course of steroid
therapy. On the other hand, only 30.9% of M/M asthma had at
least one indicator of asthma exacerbation with no patients
admitted to hospital in the preceding 12 months. Detailed
demographic and clinical characteristics of subjects included in
the study are presented in Table 1.
Since most polymorphisms of interest have a minor allele
frequency (MAF) of 15–33% in the Caucasian population, power
analysis showed that the number of recruited patient in this study
provided a sufficient sample size to detect an OR of 2.57 (with
80% power at 5% a-level) for an increased frequency of risk alleles
in patients with difficult asthma as compared to patients with
mild/moderate asthma assuming an average MAF of 23% in the
population (19% increase will be detected if MAF = 15% and 21%
increase if MAF = 33%).
Genotype and allele frequencies
Allele and genotype frequencies for each SNP selected for
investigation are shown in Table 2. All SNPs were in Hardy-
Weinberg Equilibrium (HWE) (p.0.01) in both M/M and
difficult asthmatic subgroups apart from ADRb2 C79.G
(p = 0.004 in difficult asthmatics). The latter SNP was, therefore,
excluded from analysis in the present study. All of the remaining
SNPs had a call rate .95% and a genotyping accuracy .99%.
Association between genetic variants and difficult
asthma
Possible associations between difficult asthma and the presence
of risk alleles for any of the studied polymorphisms were examined
(Table 3). The results indicated that allele A of LTA4H A-
9188.G (rs2660845), allele G of TNFa G-308.A (rs1800629)
and allele A of IL-4Ra A1727.G (rs1801275) were all signifi-
cantly associated with difficult asthma in paediatric patients after
adjusting for multiple testing (p,0.001, p = 0.019 and p = 0.037,
respectively).
A further evaluation of the genotype distribution of these
polymorphisms showed that carriers of the AA genotype of
LTA4H A-9188.G or IL-4Ra A1727.G polymorphisms and
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carriers of the GG genotype of TNFa G-308.A polymorphism
were at an increased risk of having difficult asthma when
compared with carriers of other genotypes of these polymorphisms
(OR = 3.0; 95%CI = 1.6–5.7; p = 0.001, OR = 2.4; 95%CI = 1.3–
4.6; p = 0.006 and OR = 2.2; 95%CI = 1.1–4.1; p = 0.019, respec-
tively).
Analysis of the allelic distribution among patients according to
their asthma severity also indicated nominally significant associ-
ations of allele A of IL-4Ra A1199.C, allele T of IL-4Ra
T1570.C and allele A of TNFa TNFa C-863.A with asthma
severity (p = 0.033, p = 0.018 and p = 0.047, respectively). How-
ever, these associations were not significant after correction for
multiple testing.
Linkage disequilibrium and haplotype association
analysis
In order to investigate the combined effect of more than one
SNP, haplotype analysis was carried out for the SNPs that showed
significant or nominally significant association with difficult
asthma. The results of haplotype analysis are presented in
Table 4. There was strong linkage disequilibrium (D’ = 1)
between the three selected IL-4Ra polymorphisms (A1199.C,
T1570.C and A1727.G) and between the two TNFa polymor-
phisms (C-863.A and G-308.A). These five SNPs formed two
blocks, one in each gene. LTA4H A-9188.G, however, did not
segregate with any of these SNPs, Figure 1. Two haplotypes
(ATA in the first block, chromosome 16 and CA in the second
block, chromosome 6) showed significant association with difficult
asthma, including after correction for multiple testing (p = 0.04
and p = 0.018, respectively). The ATA haplotype was the most
common haplotype in block 1 (81.9%), whereas CA was the next
most frequent in block 2 (24.2%) following GC as the most
frequent (58.1%).
Furthermore, another two haplotypes, CCG (the second most
frequent haplotype in block 1) and AG (the least frequent
haplotype in block 2) were more prevalent in children with M/
M asthma compared to those with difficult asthma (p = 0.037 and
p = 0.046, respectively). However, these associations did not reach
statistical significance after correction for multiple testing.
Table 1. Demographic and clinical characteristics of paediatric asthma patients (n = 180).
Characteristic M/M asthma (n=68)a Difficult asthma (n=112)a P value
Age at evaluation (years)b 8.7963.15 [2–15] 9.3563.80 [1–16] NS
Gender (female) 29 (42.6%) 35 (31.3%) NS
Smoking NS
Never 66 (98.5%) 105 (98.1%)
Ex-smoker 0 0
Current smoker 1 (1.5%) 2 (1.9%)
Personal history of hayfever/eczema 42 (63.6%) 82 (74.5%) NS
Family history of asthma 45 (67.2%) 86 (78.2%) NS
Family history of hayfever/eczema 46 (69.7%) 63 (64.9%) NS
At least one indicator of asthma exacerbation in the last 12
months
21 (30.9%) 101 (90.2%) ,0.001
Unscheduled visit (GP, hospital) 20 (29.4%) [0–2] 83 (75.5%) [0–14] ,0.001
Accident & emergency attendance 7 (10.3%) [0–2] 37 (34.3%) [0–10] ,0.001
Hospital admission 0 27 (24.5%) [0–10] ,0.001
Rescue steroid course 10 (14.7%) [0–1] 81 (75.7%) [0–15] ,0.001
BTS step of asthma treatment (%) ,0.001
Step 1 4 (5.9%) 0
Step 2 31 (45.6%) 0
Step 3 33 (48.5%) 0
Step 4 0 74 (66%)
Step 5 0 38 (33.9%)
Number of asthma drug categoriesb 2.260.6 [0–3] 4.160.9 [3–7] ,0.001
Use of home nebuliser ,0.001
No 52 (89.7%) 37 (33%)
Yes (as needed) 6 (10.3%) 56 (50%)
Yes (regular) 0 19 (17%)
Maintenance oral steroid 0 14 (12.6%) [2.5–50] 0.002
BDP equivalent of daily ICS (mg)b 332.06180.5 [100–800] 1247.66897.5 [200–4000] ,0.001
BTS: British Thoracic Society; GP: general practitioner; BDP: beclomethasone diproprionate; ICS: inhaled corticosteroid.
ain some cases data were missing, i.e. percentage values correspond to numbers of patients for which full data were available.
bdata presented as mean6SD; [range].
doi:10.1371/journal.pone.0060592.t001
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SNP-SNP interactions
To test for potential interaction between the polymorphisms on
affection status, polymorphisms showing the strongest association
with difficult asthma were selected, i.e. LTA4H A-9188.G,
TNFa G-308.A and IL-4Ra A1727.G. No evidence of gene-
gene interaction was observed between pairs of associated markers
Table 2. Allele and genotype frequencies of the genetic variants of interest in the study cohort (n = 360 alleles).
Genetic variant dbSNP# SNP type{ Variant allele frequency (%) Heterozygotes (%)
ADRb2 A46.G rs1042713 missense (Arg16.Gly) 36.4% 38.3%
CRHR1 G35892.T{ rs242941 synonymous 32.5% 40.6%
CRHR1 A38952.G{ rs242939 synonymous 8.1% 16.1%
CRHR1 G54898.A{ rs1876828 synonymous 19.3% 30.7%
LTC4S A-444.C rs730012 synonymous 31.8% 46.9%
LTA4H A-9188.G{ rs2660845 synonymous 27.5% 43.8%
IL-4 C-590.T rs2243250 synonymous 11.0% 19.8%
IL-4 C-33.T rs2070874 synonymous 11.5% 20.7%
L-13 C-1111.T rs1800925 synonymous 17.3% 26.8%
IL-13 G431.A rs20541 missense (Arg130.Glu) 15.7% 26.5%
IL-4Ra A223.G rs1805010 missense (Ile50.Val) 42.8% 47.8%
IL-4Ra A1199.C rs1805011 missense (Glu375.Ala) 9.2% 17.3%
IL-4Ra T1570.C rs1805015 missense (Ser478.Pro) 15.6% 28.9%
IL-4Ra A1727.G rs1801275 missense (Gln551.Arg) 18.1% 32.8%
LTA C804.A rs1041981 missense (Thr60Asn) 39.9% 47.5%
TNFa T-1031.C rs1799964 synonymous 21.9% 31.5%
TNFa C-863.A rs1800630 synonymous 17.6% 27.4%
TNFa G-308.A rs1800629 synonymous 24.0% 32.7%
{Numbering was based on RefSeqGene mapping, NCBI database.
{The polymorphism is termed missense if the nucleotide change alters the amino acid sequence, termed synonymous otherwise.
doi:10.1371/journal.pone.0060592.t002
Table 3. Association analysis between the various polymorphisms of interest and asthma phenotypes (difficult versus M/M
asthma).
Genetic variant Associated allele Difficult Asthmatics M/M Asthmatics p-value p-value (adjusted){
ADRb2 A46.G A 37.5% 34.6% 0.57 -
CRHR1 G35892.T T 34.4% 29.4% 0.32 -
CRHR1 A38952.G A 93.8% 89.0% 0.11 -
CRHR1 G54898.A G 82.0% 78.7% 0.44 -
LTC4S A-444.C C 33.3% 29.4% 0.43 -
LTA4H A-9188.G A 79.5% 61.0% 161024 0.0007
IL-4 C-590.T C 89.1% 88.8% 0.93 -
IL-4 C-33.T C 88.7% 88.2% 0.88 -
IL-13 C-1111.T T 18.0% 16.2% 0.65 -
IL-13 G431.A A 15.9% 15.2% 0.86 -
IL-4Ra A223.G A 57.6% 56.6% 0.85 -
IL-4Ra A1199.C A 93.3% 86.6% 0.033 0.14
IL-4Ra T1570.C T 87.9% 78.7% 0.018 0.091
IL-4Ra A1727.G A 86.2% 75.0% 0.007 0.037
LTA C804.A C 62.5% 56.0% 0.22 -
TNFa T-1031.C C 24.6% 17.4% 0.11 -
TNFa C-863.A A 20.7% 12.5% 0.047 0.22
TNFa G-308A G 80.8% 66.9% 0.004 0.019
{Adjusted p-values were considered when the initial uncorrected values were ,0.05.
doi:10.1371/journal.pone.0060592.t003
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(p.0.05 for all two-way interactions using UNPHASED likelihood
algorithm). Furthermore, the three SNPs, LTA4H A-9188.G,
TNFa G-308.A and IL-4Ra A1727.G, remained significant
after conditioning on the effect of each of the other associated
SNPs. This suggests that each of the 3 SNPs is exerting an
independent effect.
Discussion
Asthma medications comprise a substantial portion of health-
care expenditure. Despite new therapies becoming available in all
developed countries, there is still a significant number of non-
responders [9,28]. Evidence suggests that genetic factors may
mediate a large part of such heterogeneity in response to each of
the three major classes of asthma medications [29].
b2-agonists are the most commonly used class of medication in
the treatment of asthma worldwide [30]. b2-agonists produce
bronchodilatation (increase FEV1) in asthmatics by binding to and
directly stimulating b2-adrenoceptors on airway smooth muscle
cells. A number of polymorphisms in the gene encoding the
human b2-adrenoceptor (e.g. A46.G and C79.G polymor-
phisms which modify the amino acid sequence of the receptor into
Arg16.Gly and Gln27.Glu, respectively) have been known to
alter its function in the cardiovascular and respiratory systems. In
the airway, the presence of the homozygous Arg16 genotype (wild)
has been shown to confer relative protection against b2-
adrenoceptor down-regulation by endogenous catecholamines.
This explains the greater bronchodilator response to acute b2-
agonist therapy in Arg16 homozygotes but results in a diminished
therapeutic response to prolonged or chronic b2-agonist therapy
and reverses the benefits from the regular use of both short and
long acting b2-agonists in these patients [12,20–21]. Conversely,
down-regulation of b2-adrenoceptors in patients with the Glu27
genotype (variant) has been shown to be attenuated in comparison
with those with the Gln27 genotype (wild). Studies have shown an
increased likelihood of exacerbations among children and adults
with mild-moderate asthma who were homozygous for the Arg16
genotype when regularly dosed with short or long acting b2-
agonists [21,31–34]. The development of difficult asthma and its
association with the Arg16/Arg16 genotype or other genotypes,
however, has not been investigated before. In the present study, we
demonstrate no association between these SNPs and difficult
asthma.
The second class of asthma drugs for which pharmacogenetics
could contribute to variability in treatment response is leukotriene
antagonists. Leukotrienes are a family of potent bronchoconstric-
tors which are produced in the airways of asthmatics. Of the many
enzymes involved in the formation of leukotrienes, polymorphisms
in two (LTC4S, and LTA4H) have been associated with altered
response to leukotriene antagonists [13]. Of potential interest,
LTA4H A-9188.G SNP has been associated with a fourfold
increase in the risk of asthma exacerbations while LTC4S A-
444.C SNP has been associated with 76% reduction in
exacerbations as shown in a recent study [35]. Observational
data in difficult asthma cohorts, suggests that this class of agent has
less efficacy in this population, and again raises the possibility that
a non-responsive phenotype is found in subjects with difficult
asthma.
Interestingly, the present study revealed strong evidence for the
involvement of LTA4H A-9188.G polymorphism in the devel-
opment of difficult asthma in children. Current findings suggest
that carriers of the AA genotype are at 3-times higher risk of
Figure 1. Linkage disequilibrium (LD) structure of the exam-
ined genetic loci of interest in the study population. The
haplotype blocks were generated by Haploview using the default
algorithm [21]. Values in the boxes are D’ measures, indicating extent of
LD between two SNPs. Boxes without numbers have D’ = 1.
doi:10.1371/journal.pone.0060592.g001
Table 4. Association of the examined haplotypes with the risk of developing difficult asthma in children.
Haplotype Frequency, % (Study Cohort) Frequency ratio, % (Difficult:M/M) p-value p-value (adjusted){
Block 1: IL-4Ra (A1199.C, T1570.C and A1727.G )
ATA 81.9% 86.2%:75.0% 0.007 0.040
CCG 9.2% 6.7%:13.2% 0.037 0.187
ACG 0.6% 5.4%:8.1% 0.304 -
ATG 2.5% 1.8%:3.7% 0.265 -
Block 2: TNFa (C-863.A and -308A)
CG 58.1% 60.1%:54.9% 0.338 -
CA 24.2% 19.2%:32.6% 0.004 0.018
AG 17.6% 20.7%:12.5% 0.046 0.238
{Adjusted p-values were considered when the initial uncorrected values were ,0.05.
doi:10.1371/journal.pone.0060592.t004
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developing difficult asthma than carriers of the GG genotype.
Relative to other genes, LTA4H has not been thoroughly
examined in genetic association studies and the number of
investigations analysing the association of polymorphisms in this
gene with asthma-related phenotypes is limited [13–14,35]. To
our knowledge, this is the first study to investigate the association
between this gene and severe asthma in children.
The third class of medication used in asthma is the glucocor-
ticoids. Glucocorticoids are the most potent anti-inflammatory
agents in current routine use in the treatment of asthma. In
general, glucocorticoids activate anti-inflammatory genes and
repress the expression of pro-inflammatory cytokines [36]. Hence,
they attenuate airway inflammation and hyper-responsiveness in
asthmatic patients. Glucocorticoids are very effective in those who
respond. However, the hallmark of difficult asthma is relative
steroid resistance, resulting in the requirement for higher doses,
with resultant undesirable side-effects [37]. Many mechanisms
have been postulated to explain this relative steroid resistance,
including defects in the CRHR1 receptor, because it is a major
regulator of glucocorticoid synthesis. A recent study showed that
genotype differences in the CRHR1 gene were associated with
alterations in the therapeutic responses to inhaled corticosteroids
in asthmatic patients [15]. In the present study, however, there
was no association identified between the same three polymor-
phisms discussed earlier (G35892.T, A38952.G and
G54898.A) and difficult asthma.
Numerous other genes have been associated with asthma and
related phenotypes, including those related to T helper cell (Th)
pathways (IL-4, IL-13, IL-4Ra, TNFa and LTA) [16-17,38].
The TNF superfamily which belongs to the Th1 pathway [39],
has been shown to play an important role in the immune response
and triggering of inflammation which is of paramount importance
in the pathophysiology of asthma. TNFa and LTA genes are
clustered together on chromosome 6p21.3. Variations in these
genes have been associated with asthma through both case-control
and family-based studies, performed in diverse populations [18–
19,40–42]. Of particular interest is the TNFa G-308.A SNP
which has been associated with increased bronchial hyper-
reactivity [43] and wheezing [44–45]. In the present study, the
G allele of TNFa G-308.A SNP conferred a significant risk of
developing difficult asthma in children. Furthermore, the G-
308.A polymorphism was in strong linkage disequilibrium with
C-863.A and carriage of the CA haplotype (TNFa -863C and -
308A) has been significantly associated with difficult asthma, even
after correction for multiple testing.
In addition, polymorphisms in IL4-Ra (related to Th2 pathway)
have been associated with severity of asthma in the present study;
nominally significant associations were found between A1199.C,
T1570.C polymorphisms and difficult asthma and A1727.G
was strongly associated with difficult asthma in children after
adjustment for multiple testing. This is supported by previous
studies which observed significant associations between IL4-Ra
polymorphisms (A1199.C, T1570.C and A1727.G) and
asthma-related phenotypes [46–48]. In these studies, patients
who carried the A allele of the rs1801275 polymorphisms showed
elevated total serum IgE levels [46–47] and an increased risk of
allergic asthma [48]. The latter association was particularly
observed in patients with persistent asthma. In the present study,
the haplotype ATA (of IL4-Ra A1199.C, T1570.C and
A1727.G polymorphisms) was significantly more frequent in
children within the difficult asthma group.
In addition, polymorphisms in IL-4 (related to Th2 pathway)
have been associated with severity of asthma as measured by
FEV1 [16]. Of interest, is the C-590.T SNP which has been
associated, in a recent study, with fatal or near-fatal asthma in
adults [24]. Previous studies have also shown associations of C-
1111.T and G431.A polymorphisms in the IL-13 gene with
various features of the asthmatic phenotype [22–23]. In the
present study, however, none of these SNPs were significantly
associated with difficult asthma in our paediatric population.
One potential limitation of our study is that in the difficult
asthma group we were unable to confidently separate out children
with true severe therapy resistant asthma from those with difficult
to treat asthma for other causes. This would have required that all
such children would have been screened through an invasive
difficult asthma protocol and been observed for 3–6 months to
have adhered to optimised therapy [4]. Future studies would
benefit from this stratification. However, our original hypothesis
was best served by studying a wider group of children with difficult
asthma as this would include children who may have stopped
taking medication as it truly was not working. Another limitation
of the study is the relatively small cohort size (particularly the M/
M asthma group) which likely contributed to the wide CI ranges
and insufficient power (,80%) to detect ORs of less than 2 for
association of difficult asthma and potential SNPs particularly
those with MAF less than 15%. The present findings should,
therefore, be interpreted with caution as it is not possible to draw
definitive conclusions on the association between SNPs with
MAF,23% and asthma phenotypes without validation in a
separate cohort. Validation of the findings in a larger population is
warranted to examine the potential importance of these polymor-
phisms.
In conclusion, we have identified multiple SNPs and haplotypes
in LTA4H, TNFa and IL4-Ra genes that constitute risk factors for
the development of difficult asthma in children and demonstrate
combined effects which confer greater risk than that obtained for
any SNP individually. Functional studies focusing on the potential
clinical implications of these findings are warranted. For example,
our results suggest that screening for the associated genetic
markers may identify individuals at risk of developing difficult
asthma. Furthermore, our data suggest that LTA4H genetic
variations could play an important role in the wide inter-patient
variability of responses to leukotriene antagonists. A greater
understanding of the molecular mechanisms underlying the effect
of these genetic variations could provide insight into the overall
mechanisms that cause susceptibility to difficult asthma and,
hence, lead to new therapeutic opportunities for the treatment of
this complex disease in children. It could also help characterise the
heterogeneity of responses to leukotriene-modifying medications
and facilitate targeting such therapies to the subset of asthmatic
patients who are most likely to gain benefit.
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